Recombinant tissue plasminogen activator (tPA)—a molecule approved for the treatment of acute stroke by the FDA in ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold ...

Effective treatment for Demodex blepharitis includes antibiotics, steroids, and lotilaner ophthalmic solution, which resolves ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

Eyecyte-RPE phase 1 study showed promising safety and efficacy, with no serious adverse events and significant vision ...

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...